CD19 and neoplasm: In this context, it is important to note that the only study reporting a consistent number of B-lymphoma patients treated with iPSC-derived CD19 CAR-NK cells showed a clear relationship between CAR-NK cell dose-infused and their in vivo expansion, but failed to show a clear correlation between CAR-NK expansion and anti-tumor response [26].